Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CTO Metin Kurtoglu sold 2,417 shares of the firm's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $16.72, for a total transaction of $40,412.24. Following the completion of the sale, the chief technology officer now owns 64,716 shares in the company, valued at $1,082,051.52. This represents a 3.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Metin Kurtoglu also recently made the following trade(s):
- On Monday, January 6th, Metin Kurtoglu sold 2,458 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $16.83, for a total value of $41,368.14.
- On Thursday, November 21st, Metin Kurtoglu sold 32,789 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $16.67, for a total value of $546,592.63.
- On Monday, November 18th, Metin Kurtoglu sold 34,400 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $18.39, for a total value of $632,616.00.
- On Thursday, November 14th, Metin Kurtoglu sold 25,900 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $16.44, for a total transaction of $425,796.00.
Cartesian Therapeutics Stock Performance
Shares of NASDAQ RNAC traded down $0.47 during trading on Tuesday, reaching $17.16. The stock had a trading volume of 105,686 shares, compared to its average volume of 132,021. The company has a market cap of $436.12 million, a P/E ratio of -0.32 and a beta of 0.56. The business's 50-day moving average price is $19.32 and its 200-day moving average price is $18.19. Cartesian Therapeutics, Inc. has a fifty-two week low of $11.66 and a fifty-two week high of $41.87.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in shares of Cartesian Therapeutics by 0.9% during the third quarter. JPMorgan Chase & Co. now owns 309,018 shares of the company's stock worth $4,981,000 after buying an additional 2,688 shares in the last quarter. Barclays PLC lifted its holdings in Cartesian Therapeutics by 208.6% during the 3rd quarter. Barclays PLC now owns 11,611 shares of the company's stock worth $188,000 after buying an additional 7,849 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Cartesian Therapeutics by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 135,700 shares of the company's stock valued at $2,188,000 after acquiring an additional 2,737 shares during the last quarter. State Street Corp raised its position in shares of Cartesian Therapeutics by 2.5% during the 3rd quarter. State Street Corp now owns 157,495 shares of the company's stock worth $2,539,000 after acquiring an additional 3,830 shares in the last quarter. Finally, Great Point Partners LLC purchased a new stake in Cartesian Therapeutics during the third quarter worth approximately $3,224,000. 86.95% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
RNAC has been the topic of a number of research analyst reports. Needham & Company LLC reissued a "buy" rating and set a $41.00 price objective on shares of Cartesian Therapeutics in a report on Tuesday, December 3rd. Cantor Fitzgerald upgraded Cartesian Therapeutics to a "hold" rating in a research report on Monday, December 2nd. HC Wainwright reissued a "buy" rating and set a $45.00 price target (up from $41.00) on shares of Cartesian Therapeutics in a research report on Wednesday, December 4th. Finally, BTIG Research assumed coverage on shares of Cartesian Therapeutics in a research report on Thursday, December 19th. They set a "buy" rating and a $42.00 target price for the company. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $42.86.
View Our Latest Stock Report on RNAC
About Cartesian Therapeutics
(
Get Free Report)
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cartesian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.
While Cartesian Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
